Basic Information
| LncRNA/CircRNA Name | HOXA13 |
| Synonyms | HOXA13, HOX1, HOX1J |
| Region | GRCh38_7:27193503-27200106 |
| Ensemble | ENSG00000106031 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | sorafenib | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Microarray |
| Sample | hepatocellular carcinoma tissues |
| Expression Pattern | up-regulated |
| Function Description | patients with HOXA13-positive HCC had worse overall survival than those with HOXA13-negative HCC. HOXA13 and HOTTIP were expressed in the same neoplastic hepatocyte populations.Stable overexpression of HOXA13 in liver cancer cell lines resulted in increased colony formation on soft agar and migration potential as well as reduced sensitivity to sorafenib in vitro. |
| Pubmed ID | 29035381 |
| Year | 2017 |
| Title | High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. |
External Links
| Links for HOXA13 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |